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Society for Developmental Perinatal &
Paediatric Pharmacology, in Chamonix,
France in 2009.
Dear Editor,
Low cardiac output syndrome
(LCOS) affects approximately 25%
of children undergoing open heart
surgery (OHS) and is associated with
increased morbidity and mortality [1].
Evidence for preventive drug therapy
for LCOS is derived primarily from
the PRIMACORP study [1], which
reported a reduction in LCOS risk
after administration of high-dose
milrinone, using a bolus of 75 lg/kg,
followed by a maintenance infusion
of 0.75 lgk g
-1 min
-1 over 35 h.
Low-dose milrinone (25 lg/kg bolus
and 0.25 lgk g
-1 min
-1 infusion)
was not more effective than placebo.
Other drugs may be also used but are
not supported by safety and efﬁcacy
data [2, 3]. Data on drug use for
LCOS prevention in children with
OHS is not available for Europe.
Therefore, the aim of this study was
to characterise hospital practices
related to preventive drug therapy for
LCOS in children undergoing OHS as
a basis for improving the standard of
care in this setting.
A Web-based questionnaire was
developed to survey 125 specialised
hospitals from 36 European countries
between January and August 2009. It
included 15 questions allocated to 4
sections: prescribing resources and
LCOS treatment (data not shown),
LCOS prevention, and participant
characteristics and comments. The
questions on LCOS prevention
enquired about the target patient
group (all, at risk, none) and mode of
drug administration, which was not
further stratiﬁed. The hospitals were
notiﬁed by email; of those, 90 hos-
pitals from 31 countries responded
(72.0% response rate). Respondents
included clinicians (98.9%) and
pharmacists (1.1%), specialising pri-
marily in paediatric intensive care,
anaesthesiology, cardiology, and car-
diothoracic surgery. Nearly all
respondents (94.4%) had at least
5 years of experience in caring for
children undergoing OHS.
Most European hospitals (70 out of
90) reported preventive drug therapy
for LCOS, from which the majority
(57 hospitals) selectively targeted
patients at risk. However, the drug
use was highly variable. In total, 24
different drug regimens were repor-
ted, including 17 drugs from 7
therapeutic drug classes. Overall,
70.7% of the drug regimen reports
included milrinone, making this the
most commonly used drug. Dopa-
mine, dobutamine, epinephrine, and
levosimendan were reported signiﬁ-
cantly less often (Table 1). The
dosage and duration of drug admin-
istration differed substantially among
hospitals.
The results of this survey present
the current pattern of drug use for
LCOS prevention in children with
Table 1 Summary characteristics of the drugs commonly reported for LCOS prevention
Drug
a Frequency of drug use Drug administration
N % 95% CI Bolus
b
(lg/kg)
Maintenance infusion
b
(lgk g
–1 min
–1)
Duration
b
(h)
Milrinone 53 70.7 59.6–79.8 50 (20–300) 0.5 (0.2–1.5) 39 (6–168)
Dopamine 14 18.7 11.5–28.9 –
c 5 (0–15) 36 (8–72)
Dobutamine 12 16 9.4–25.9 7
d (6–8) 5 (2–14) 36 (6–48)
Epinephrine 12 16 9.4–25.9 1 (1–1) 0.065 (0.003–0.3) 9 (6–12)
Levosimendan 12 16 9.4–25.9 12 (12–12) 0.15 (0.1–0.2) 24 (24–48)
Methylprednisolone 4 5.3 2.1–12.9 25
e (10–35) – –
The analysis was based on 75 drug regimens reported from 69
hospitals. Two hospitals provided three different drug regimens and
another two hospitals provided two drug regimens based on the
clinical condition of the patient and the type of open heart surgery.
One hospital did not ﬁll in the information on drug dosing
a Only 6 out of 17 drugs were reported more than twice and are
listed in the table. The following drugs were reported once or twice:
alprostadil, bosentan, calcium, enoximone, glyceryl trinitrate,
inhaled nitric oxide, norepinephrine, phenoxybenzamine, phenyl-
ephrine, nitroprusside, and thiopental
b Data are median with range in parenthesis
c Not reported
d Bolus dose in lgk g
-1 min
-1
e Bolus dose in mg/kg
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acterised by a marked variability. In
addition, the dose of milrinone
appears to be lower than that sup-
ported by PRIMACORP. Although
our survey shows that milrinone is the
most frequently used drug in Europe,
neither the dosing nor the duration of
drug administration coincide with
those demonstrating efﬁcacy in PRI-
MACORP (Table 1). Reasons for the
reduced dose of milrinone may be
attributable to concerns about poten-
tial side effects, especially
hypotension [4], and the role of age-
speciﬁc pharmacokinetic differences
in the elimination of milrinone [5].
Nonetheless, these factors cannot
explain the generally lower dose of
milrinone used across all paediatric
age groups, which needs to be
addressed in future clinical research.
In summary, preventive drug ther-
apy for LCOS in children undergoing
OHS is highly variable across Europe,
and the data available to support
current hospital practices are insufﬁ-
cient. Given the importance of
balancing beneﬁts and risks with
preventive drug therapy, this survey
emphasises the need for further stud-
ies that will substantiate effective and
safe LCOS prevention.
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